SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?


To: Cacaito who wrote (2111)2/27/2002 1:23:32 PM
From: The Fox  Read Replies (1) | Respond to of 2515
 
With apologies to Wm. Shakespeare...

The [poster] doth protest too much mee thinks (Queen, in Hamlet (Quarto 2) 3.2)

Cacaito...you are much too emotional about this situation to be a mere bystander.

There doesn't seem to be much question among the people who participated in the trails that the drug works. Now, IMCL and BMY, with Merck's help, will move it through the approval process. These delays are not uncommon; many, many companies have received RTF letters and have gone on to work out their problems with the FDA. Were all of them run by officers who's sole intent was to bank investors' monies? I don't think so. The problem here was that the RTF letter was leaked and the process was disrupted. There is indication, in fact, that the FDA - and not ImClone - is the real culprit here (you did read the WSJ today, didn't you?). I think your anger is misdirected.

This all will pass. C225 will be approved. If not this year, then the next. Lives will be saved. Ranting and raving about something over which you and I have no control is neither helpful nor healthy.

The Fox

Full disclosure...I am long: 1750 shares at $39/share. This is one of 12 biotechs I own. I am perfectly content to wait. It's always paid off in the past (and I've invested in biotechs since 1980). The Fox



To: Cacaito who wrote (2111)2/27/2002 1:31:44 PM
From: 613  Read Replies (1) | Respond to of 2515
 
Doesn't tumor shrinkage generally corollate with longer life?



To: Cacaito who wrote (2111)2/27/2002 3:30:03 PM
From: 613  Read Replies (1) | Respond to of 2515
 
also - from WSJ story -"Thirty-three percent of patients in the Erbitux trial lived beyond one year, he says, compared with only about 18% in studies of a similar patient population taking chemotherapy alone, he says."



To: Cacaito who wrote (2111)3/1/2002 6:12:51 PM
From: telephonics  Respond to of 2515
 
You stated your positionm very well. However, I don't happen to agree with you.